Cardiorenalmetabolic

The history of women being left out of heart disease research has had significant consequences on heart health care today.

Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).

Unmet social needs in certain neighborhoods contribute to disparities in diabetes care, leading to greater reliance on emergency services, fewer preventive measures, and higher rates of complications.

Women are still being excluded from cardiovascular research trials, and it has a lasting impact on heart disease treatment for women today.

UMass Memorial Health–Harrington Hospital reduced 30-day readmissions for congestive heart failure by 50% using artificial intelligence and remote care teams.

This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.

Despite being eligible for guideline-directed medical therapy (GDMT), tens of millions of patients across the globe are not receiving the heart failure care they need.

The 2024 Trends Shaping the Health Economy report gave a past, present, and future look at diabetes care in the US and the role of obesity in these trends.

The innovative program from the Family Heart Foundation includes being able to order a free test kit for an at-home blood lipid panel and track your results online, as well as the ability to discuss the findings with care navigators and health care providers.

Inconsistent adherence to the guidelines led to delayed heart failure treatment optimization and underutilization of key therapies.

Hospitals that better utilized heart failure guideline-directed medical therapy (GDMT) had better patient outcomes, with lower mortality rates and costs.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.

On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.

New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.

This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.

Ian Neeland, MD, of University Hospitals and Case Western Reserve University, recommended a team-based, comprehensive approach to managing diabetes and its related complications.

Manisha Jhamb, MD, MPH, of the University of Pittsburgh Medical Center (UPMC), is excited about CMS's negotiated drug prices under the Inflation Reduction Act (IRA) for patients with kidney disease; conversely, she highlights the challenge of low kidney disease awareness.

New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in the V-MONO study.

Research at the European Society of Cardiology Congress 2024 evaluated lipid-lowering therapy beyond statins alone in patients with high levels of low-density lipoprotein cholesterol.

Regardless of duration of type 2 diabetes, sodium-glucose cotransporter inhibitors prevented cardiovascular events, according to research presented at the European Society of Cardiology Congress 2024.

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.

New research indicates that the heart benefits of semaglutide can extend to those with heart failure.

Heart failure mortality rates after hospital discharge have seen little improvement since 2010 among Medicare beneficiaries, with real-world outcomes falling short of clinical trial expectations.